CoChat

Paraneoplastic Thrombocytosis in Ovarian Cancer

Open access

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The mechanisms of paraneoplastic thrombocytosis in ovarian cancer and the role that platelets play in abetting cancer growth are unclear. METHODS: We analyzed clinical data on 619 patients with epithelial ovarian cancer to test associations between platelet counts and disease outcome. Human samples and mouse models of epithelial ovarian cancer were used to explore the underlying mechanisms of paraneoplastic thrombocytosis. The effects of platelets on tumor growth and angiogenesis were ascertained. RESULTS: Thrombocytosis was significantly associated with advanced disease and shortened survival. Plasma levels of thrombopoietin and interleukin-6 were significantly elevated in patients who had thrombocytosis as compared with those who did not. In mouse models, increased hepatic thrombopoietin synthesis in response to tumor-derived interleukin-6 was an underlying mechanism of paraneoplastic thrombocytosis. Tumor-derived interleukin-6 and hepatic thrombopoietin were also linked to thrombocytosis in patients. Silencing thrombopoietin and interleukin-6 abrogated thrombocytosis in tumor-bearing mice. Anti-interleukin-6 antibody treatment significantly reduced platelet counts in tumor-bearing mice and in patients with epithelial ovarian cancer. In addition, neutralizing interleukin-6 significantly enhanced the therapeutic efficacy of paclitaxel in mouse models of epithelial ovarian cancer. The use of an antiplatelet antibody to halve platelet counts in tumor-bearing mice significantly reduced tumor growth and angiogenesis. CONCLUSIONS: These findings support the existence of a paracrine circuit wherein increased production of thrombopoietic cytokines in tumor and host tissue leads to paraneoplastic thrombocytosis, which fuels tumor growth. We speculate that countering paraneoplastic thrombocytosis either directly or indirectly by targeting these cytokines may have therapeutic potential. (Funded by the National Cancer Institute and others.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1110352

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Research works printed but not linked: 2

  1. Riess L, 1872, Arch Anat Physiol Wissensch Med, 39, 237
  2. Akl EA, 2007, Cochrane Database Syst Rev, 3, CD006652

Cited by

Metadata

Authors
Stone, R. L., Nick, A. M., McNeish, I. A., Balkwill, F., Han, H. D., Bottsford-Miller, J., Rupaimoole, R., Armaiz-Pena, G. N., Pecot, C. V., Coward, J., Deavers, M. T., Vasquez, H. G., Urbauer, D., Landen, C. N., Hu, W., Gershenson, H., Matsuo, K., Shahzad, M. M. K., King, E. R., Tekedereli, I., Ozpolat, B., Ahn, E. H., Bond, V. K., Wang, R., Drew, A. F., Gushiken, F., Lamkin, D., Collins, K., DeGeest, K., Lutgendorf, S. K., Chiu, W., Lopez-Berestein, G., Afshar-Kharghan, V., & Sood, A. K.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Queen Mary University of London (GB)
  • University of Alabama at Birmingham (US)
  • University of Maryland, Baltimore (US)
  • University of Cincinnati (US)
  • University of Iowa Holden Comprehensive Cancer Center (US)
Venue
New England Journal of Medicine
Published
2012-02-16
Volume
366
Issue
7
Pages
610-618
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2117600467
Cited by
812
References
26
Citations by year
2026: 39 · 2025: 45 · 2024: 71 · 2023: 53 · 2022: 81 · 2021: 58 · 2020: 64 · 2019: 50 · 2018: 55 · 2017: 81 · 2016: 58 · 2015: 58 · 2014: 47 · 2013: 28 · 2012: 23
FWCI
33.20
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
Funders
  • U.S. Department of Defense (RC2GM092599, U54 CA151668, CA128797, BC085265, OC073399)
  • Ovarian Cancer Research Fund
  • RGK Foundation
  • Queen Mary University of London
  • Laura and John Arnold Foundation (BC085265, RC2GM092599, U54 CA151668, CA128797)
  • Marcus Foundation
  • National Institutes of Health (CA- 016672, BC085265, CA098258, CA083639)
  • Medical Research Council
  • National Cancer Institute (CA 109298, CA 016672, P50CA098258, U54CA151668, CA 101642, R01CA109298, T32CA009666, CA009666, CA140933, R01CA104825, R01CA140933, R01CA128797, P50CA083639, CA098258, P30CA016672, T32CA101642, CA 128797)
  • National Institute of General Medical Sciences (RC2GM092599)
Topics
  • Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
  • Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
Keywords
epithelial ovarian cancer, thrombopoietin, interleukin-6, platelets, tumor growth, angiogenesis, paclitaxel, antiplatelet therapy, survival, paracrine signaling
MeSH terms
Interleukin-6 Inhibitors, Animals, Antibodies, Monoclonal, Blood Platelets, Disease Models, Animal, Female, Humans, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Paraneoplastic Syndromes, Platelet Count, Thrombocytosis, Thrombopoietin, Signal Transduction, Interleukin-6, Proportional Hazards Models, Mice, Knockout, Disease-Free Survival, Receptors, Interleukin-6, Mice, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.